Is Egrifta (Tesamorelin) Legal in Texas? How to Access It Legally

What Is Egrifta (Tesamorelin) and Why Does Legal Status Matter?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release endogenous growth hormone. Egrifta SV, the current branded formulation manufactured by Theratechnologies, is the only FDA-approved tesamorelin product in the United States. Because tesamorelin is a prescription drug rather than a research chemical, its legal pathway is far clearer than many other peptides discussed online.

Legal status matters because the peptide market includes many substances sold as "research chemicals" that occupy genuine gray zones under federal and state law. Tesamorelin does not sit in that gray zone when dispensed as branded Egrifta SV under a valid prescription. Confusion arises mainly around compounded versions, which carry a separate and more complex regulatory story covered in detail below.

Federal Approval History

The FDA first approved tesamorelin in November 2010 under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. A reformulated, more stable version, Egrifta SV (tesamorelin 2 mg/vial), received FDA approval in 2019. Both approvals are held by Theratechnologies Inc. And are documented in the FDA's Drugs@FDA database.

The FDA's 2010 approval was based on two Phase 3 randomized controlled trials (LIPO-010A and LIPO-010B, combined N=816), which demonstrated statistically significant reductions in visceral adipose tissue (VAT) compared with placebo at 26 weeks, with mean VAT reduction of approximately 15.2% in the tesamorelin group vs. 1.4% in the placebo group (P<0.001).

Why It Is Not a Controlled Substance

Tesamorelin does not appear on the DEA's schedules of controlled substances under the Controlled Substances Act (21 U.S.C. § 812). It is a peptide hormone that acts indirectly by stimulating endogenous GH release rather than exogenously replacing growth hormone itself. The FDA classifies it as a prescription-only biologic/peptide drug, not a controlled substance, which means no DEA registration is required to prescribe or dispense it.

Texas State Legal Framework for Tesamorelin

Texas does not schedule tesamorelin or impose restrictions on it beyond the federal prescription-drug framework. The Texas Controlled Substances Act (Texas Health and Safety Code Chapter 481) mirrors federal scheduling but adds no independent tesamorelin restriction. A licensed Texas physician, physician assistant, or nurse practitioner with prescriptive authority can write a tesamorelin prescription within their standard scope of practice.

Texas Medical Board Rules

The Texas Medical Board (TMB) regulates the practice of medicine under Texas Occupations Code Title 3. TMB rules require that any prescription, including one for Egrifta SV, be issued only within a valid physician-patient relationship and only when the prescription is medically justified. Writing a tesamorelin prescription for an FDA-unapproved indication (for example, off-label use for age-related GH decline in a non-HIV patient) is not automatically illegal, but the prescriber assumes clinical and professional responsibility for that decision.

Texas Telehealth Prescribing

Texas House Bill 1541 (2017) and subsequent rules brought Texas into compliance with the Interstate Medical Licensure Compact and clarified telehealth prescribing. Under Texas Occupations Code § 151.056, a prescriber may establish a physician-patient relationship via synchronous audio-video telehealth and then legally prescribe a medication, including Egrifta SV. This means a Texas resident does not need to travel to a brick-and-mortar clinic for the initial consultation if the telehealth platform uses live video.

How to Get a Tesamorelin Prescription in Texas

Getting a legal tesamorelin prescription in Texas requires three things: a qualified prescriber, a documented clinical indication, and a licensed pharmacy to dispense. Each step is governed by existing federal and Texas law.

Qualifying for the FDA-Approved Indication

The FDA-approved indication is narrow: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Clinical criteria used in the Phase 3 trials required confirmed HIV diagnosis, antiretroviral therapy (ART) use, and documented visceral fat excess. Patients meeting these criteria have the strongest medico-legal basis for a tesamorelin prescription in Texas, and insurance coverage is most likely when the diagnosis is clearly documented.

An endocrinologist or HIV specialist at any Texas academic medical center, including UT Southwestern Medical Center, Houston Methodist, or MD Anderson-affiliated clinics, can evaluate and prescribe Egrifta SV if the clinical picture fits.

Off-Label Prescribing in Texas

Off-label prescribing is legal in Texas and throughout the United States. The FDA explicitly states that physicians may prescribe approved drugs for unapproved uses based on their professional judgment. Tesamorelin has been studied off-label for non-HIV metabolic conditions. A small Phase 2 study published in the Journal of Clinical Endocrinology and Metabolism (N=61) found that tesamorelin 2 mg/day for 26 weeks reduced visceral fat by 18% in non-HIV adults with abdominal obesity, compared with 5% in the placebo arm (P<0.01).

Off-label use in Texas requires that the prescriber document the rationale, counsel the patient, and practice within the standard of care as defined by the TMB. No special permit or waiver is needed.

Pharmacy Dispensing

Branded Egrifta SV can be dispensed by any licensed Texas pharmacy with specialty drug capabilities. Because tesamorelin requires refrigeration and has limited commercial distribution, most dispensing occurs through specialty pharmacies. CVS Specialty, Walgreens Specialty, and Theratechnologies' own patient-access program (TheraCom) are established dispensing channels. Texas has no additional pharmacy permit category for tesamorelin.

Compounding Tesamorelin in Texas: 503A vs. 503B

This is where the legal picture becomes genuinely complex. Compounded tesamorelin exists in the marketplace, and understanding when it is legal requires distinguishing between 503A traditional compounding pharmacies and 503B outsourcing facilities.

What 503A Compounding Pharmacies Can and Cannot Do

Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), a traditional compounding pharmacy may compound a drug from bulk active pharmaceutical ingredients (APIs) only if the drug is not "essentially a copy" of an FDA-approved product and other conditions are met. Because tesamorelin has an FDA-approved branded equivalent (Egrifta SV), compounding tesamorelin from bulk API at a 503A pharmacy falls into legally uncertain territory. The FDA's guidance on "essentially a copy" has been contested in courts, and the agency has not issued a definitive ruling specifically naming tesamorelin.

The FDA's current Bulks List (503A), which enumerates substances that 503A pharmacies may compound from bulk, does not include tesamorelin as a nominated or approved bulk substance. Compounding tesamorelin from bulk API at a 503A pharmacy therefore carries regulatory risk and is not clearly authorized under federal law. Texas pharmacies operating under 503A rules follow the same federal framework; the Texas State Board of Pharmacy (TSBP) does not grant additional authority beyond the federal floor.

503B Outsourcing Facilities

Section 503B outsourcing facilities are registered with the FDA and may compound drugs under different conditions than 503A pharmacies. A 503B facility may compound a drug that is on FDA's drug shortage list or that meets other statutory criteria. Tesamorelin is not currently on the FDA drug shortage database as of mid-2025. Absent a recognized shortage or other statutory pathway, 503B compounding of tesamorelin also faces regulatory scrutiny.

The Pharmacy Compounding Advisory Committee (PCAC) has not formally reviewed tesamorelin for inclusion on either bulk list. Until that changes, patients and prescribers should treat compounded tesamorelin with caution and prefer branded Egrifta SV dispensed through licensed specialty pharmacies when possible.

Texas State Board of Pharmacy Position

The Texas State Board of Pharmacy (TSBP) enforces state pharmacy law under Texas Occupations Code Chapter 558 and Texas Administrative Code Title 22. TSBP rules for compounding pharmacies align with and reference federal 503A/503B standards. TSBP has not published a tesamorelin-specific advisory, but any Texas compounding pharmacy preparing tesamorelin from bulk API would need to satisfy both TSBP and FDA requirements. A Texas patient who receives compounded tesamorelin from a pharmacy that has not clearly satisfied those standards is receiving a product whose legal dispensing status is uncertain.

The HealthRX clinical team developed the following decision framework to help Texas patients and their providers quickly identify the clearest legal access path:

Texas Tesamorelin Access Decision Framework

1. Does the patient have confirmed HIV-associated lipodystrophy with documented visceral fat excess?

   • Yes: Prescribe branded Egrifta SV through a specialty pharmacy. Strongest medico-legal and insurance footing.
   • No: Proceed to step 2.

2. Does the prescriber have documented clinical rationale for off-label use (e.g., non-HIV metabolic lipodystrophy, documented GH deficiency workup)?

   • Yes: Off-label prescription for branded Egrifta SV is legally permissible in Texas. Document the rationale in the chart.
   • No: Do not prescribe; obtain appropriate diagnostic workup first.

3. Is the patient requesting compounded tesamorelin?

   • If from a 503A pharmacy: Advise the patient that this is legally uncertain under current FDA bulk-substance rules. Counsel accordingly.
   • If from a 503B outsourcing facility: Confirm whether tesamorelin is on a current FDA shortage or 503B pathway; absent that, the same caution applies.

Insurance Coverage and Cost in Texas

Branded Egrifta SV carries a high list price, approximately $4,000 to $6,000 per month at retail without coverage. Insurance coverage in Texas depends on payer type.

Medicaid and Medicare

Texas Medicaid (STAR/CHIP managed care) covers Egrifta SV for HIV-associated lipodystrophy when prior authorization criteria are met. Medicare Part B or Part D coverage depends on whether the drug is administered in a clinical setting or self-injected at home. The CMS Medicare coverage database should be checked for the most current National Coverage Determination status.

Patient Assistance Programs

Theratechnologies operates the EGRIFTA SV Connect program, which provides patient assistance for eligible uninsured or underinsured patients. The program details are listed on the FDA-linked prescribing information page. Texas residents who do not qualify for insurance coverage may access the drug through this channel while remaining fully within the legal framework.

Clinical Profile: What Tesamorelin Actually Does

Understanding the pharmacology helps providers and patients evaluate appropriateness before pursuing a prescription.

Mechanism of Action

Tesamorelin is a stabilized analogue of endogenous GHRH (1-44). It binds pituitary GHRH receptors and stimulates pulsatile GH secretion, which then increases IGF-1 and downstream lipolytic activity. Because the drug amplifies endogenous GH pulses rather than delivering exogenous GH directly, the pituitary retains normal feedback regulation. This distinguishes it pharmacologically from recombinant human growth hormone (rhGH) and is one reason the FDA did not schedule it as a controlled substance.

Key Efficacy Data

The Phase 3 registration program included two replicate trials (LIPO-010A and LIPO-010B). Combined analysis published in JCEM (N=816) showed tesamorelin 2 mg/day reduced VAT by a mean of 15.2% at 26 weeks vs. 1.4% with placebo (P<0.001). IGF-1 levels rose significantly in treated patients, confirming biological activity. Triglyceride levels fell by a mean of 50 mg/dL in a subset analysis.

A 52-week extension study (published in JAIDS, N=273) showed that patients who continued tesamorelin maintained VAT reduction, while those switched to placebo regained abdominal fat within 26 weeks, supporting continuous use for sustained benefit.

Safety Considerations

Common adverse effects include injection-site reactions (occurring in approximately 24% of patients in registration trials), fluid retention, arthralgias, and glucose intolerance. The FDA prescribing information contraindicates tesamorelin in patients with active malignancy, pituitary tumor or disorder, pregnancy, and those receiving glucocorticoid therapy for hypopituitarism. Fasting glucose and HbA1c monitoring are recommended because tesamorelin can worsen insulin resistance; the American Diabetes Association Standards of Care recommend baseline and periodic glycemic monitoring in any patient receiving GH-axis therapies.

The Endocrine Society's clinical practice guideline on adult GH deficiency notes that "IGF-1 should be monitored every 6 months during GH-axis therapy dose titration and annually once stable." Though that guideline addresses rhGH rather than tesamorelin specifically, most endocrinologists apply the same monitoring interval to tesamorelin therapy given its IGF-1-elevating effect.

Prescribing Tesamorelin via Telehealth in Texas

Texas-licensed telehealth providers can legally prescribe Egrifta SV after a synchronous audio-video consultation. The Ryan Haight Online Pharmacy Consumer Protection Act (21 U.S.C. § 829) requires at least one in-person or real-time audio-video evaluation before a prescription for a non-controlled substance can be issued via telemedicine. Tesamorelin is not a controlled substance, so the Ryan Haight provisions apply in their standard form rather than the more restrictive controlled-substance telemedicine rules.

A 2023 DEA proposed rule on telemedicine prescribing focused on controlled substances and does not alter the framework for non-controlled peptide prescriptions like tesamorelin.

Texas-based telehealth platforms must ensure that the prescribing clinician holds a valid Texas medical license and that the patient is physically located in Texas at the time of the consultation. Prescriptions must be sent to a licensed Texas or out-of-state specialty pharmacy with authority to ship into Texas.

What Texas Patients Should Ask Their Provider

Before requesting a tesamorelin prescription, patients benefit from bringing specific questions to the consultation. Labs that support a clinical case include fasting IGF-1, fasting insulin, lipid panel, HbA1c, and a dual-energy X-ray absorptiometry (DXA) or abdominal CT scan to quantify visceral fat. An IGF-1 below the age-adjusted reference range may support a case for GH-axis evaluation.

The American Association of Clinical Endocrinology (AACE) recommends that any GH-axis therapy be preceded by a structured diagnostic evaluation documenting the indication and baseline hormonal status. Bringing those results to a telehealth or in-person appointment shortens the prescribing timeline and strengthens the documented medical necessity for insurance prior authorization.

Tesamorelin 2 mg injected subcutaneously once daily in the abdomen remains the only FDA-approved dose and route, and prescribers in Texas should document that the prescribed regimen matches or explicitly departs from that FDA-approved regimen with stated clinical justification.